Table I.
Characteristics of the main studies investigating the effect of ABO blood group on survival in patients with cancers.
| First author, yearref. | Study design | Population | Results |
|---|---|---|---|
| Dandona, 201038 | Retrospective | 417 patients undergoing resection for pancreatic cancer | No statistically significant difference in OS among different blood groups (p=0.196) was found |
| Ben, 201139 | Prospective | 1,431 patients with pancreatic cancer | The median OS in patients with blood type O was significantly longer than that of patients with non-O blood types (16.0 months vs 11.0 months, p=0.001) |
| Rahbari, 201231 | Prospective | 627 patients undergoing resection for pancreatic cancer | Blood group O was independently associated with OS (HR: 0.78; 95% CI: 0.62–0.99; p=0.037) |
| Wang, 201240 | Prospective | 488 patients with pancreatic cancer | ABO blood type was not associated with OS (non-O vs O HR: 1.150; 95% CI: 0.931–1.420; p=0.194) |
| Kaffenberger, 201232 | Retrospective | 900 patients undergoing surgery for renal cell carcinoma | In a multivariate analysis, non-O blood type was significantly associated with decreased OS (HR: 1.68; 95% CI: 1.18–2.39, p=0.004) |
| de Martino, 201442 | Retrospective | 556 patients undergoing surgery for renal cell carcinoma | ABO blood type was not associated with OS (non-O vs O HR: 0.72; 95% CI: 0.48–1.10; p=0.13) |
| Lee, 201543 | Retrospective | 3,172 patients undergoing surgery for renal cell carcinoma | ABO blood group was not associated with OS (p=0.990) |
| Orihuela, 198744 | Retrospective | 494 patients with superficial bladder cancer | Progression to advanced disease was more frequent among patients with O blood type than in those with other groups (37% vs 12–16%; p<0.05) |
| Klatte, 201445 | Retrospective | 931 patients with non-muscle invasive bladder cancer | Patients with O blood type had worse recurrence and progression rates than those with type A (p=0.015 and 0.031) or B (p=0.004 and 0.075), respectively |
| Raitanen, 199346 | Retrospective | 261 patients with bladder cancer | No differences in the mortality rate were observed among patients with different ABO blood types |
| Yamada, 199347 | Retrospective | 538 patients with bladder cancer | No significant differences among blood groups for stage, histological grade or survival rate were observed |
| Klatte, 201449 | Retrospective | 7,906 patients with bladder cancer undergoing radical cystectomy | No relevant association of ABO blood type with prognosis was detected by multivariable analysis |
| Ouyang, 201351 | Retrospective | 2,117 patients with nasopharyngeal carcinoma | Blood type A patients had significantly lower OS compared with non-O blood types (HR: 1.49, 95% CI: 1.03–2.17; p=0.036) |
| Zhang, 201452 | Retrospective | 1,601 patients with non-metastatic nasopharyngeal carcinoma | ABO blood group was not associated with OS (HR non-A vs A: 1.136, 95% CI: 0.840–1.537; p=0.408) |
| Lee, 199156 | Retrospective | 164 patients with non-small cell lung cancer | Median OS was significantly shorter in patients with primary tumour negative for blood group antigen A compared with those with antigen A-positive tumour (p<0.001) |
| Graziano, 199757 | Retrospective | 260 patients with resected early-stage non-small cell lung cancer | Median OS was significantly shorter in patients with primary tumours negative for blood group antigen A compared with those with antigen A-positive tumours (38 months vs 98 months, p<0.01) |
| Leòn-Atance, 201259 | Retrospective | 402 patients with stage I non-small cell lung cancer | The 5-year cumulative survival was 73% for patients expressing blood group antigen A vs 53% for patients with loss of expression (p=0.03) |
| Nozoe, 200461 | Retrospective | 284 patients with esophageal squamous cell carcinoma | No association between ABO blood group and prognosis was observed |
| Sun, 201462 | Retrospective | 511 patients with with esophageal squamous cell carcinoma | Among patients who had ever smoked, B/O blood group independently correlated with unfavourable survival (B/O vs A/AB: HR: 1.565, 95% CI: 1.110–2.205; p=0.011) |
| Qiu, 201166 | Retrospective | 474 patients with gastric adenocarcinoma/404 controls | No significant difference between ABO blood group and OS was observed (5-year OS B/O vs A/AB: 52.8% vs 43.0%; p=0.157) |
| Cao, 201468 | Retrospective | 1,555 patients with surgically resected colon cancer | Patients with AB blood type had a better mean OS than those with non-AB blood type (113.9 months vs 106.1 months; p<0.001). |
| Holdsworth, 198570 | Retrospective | 1,001 patients with invasive breast cancer | Patients with B and AB blood types had a poorer OS than those with O and A blood groups (p=0.015) |
| Gates, 201173 | Prospective | 3,107 patients with breast cancer | No association between blood type and breast-cancer specific mortality was found |
| Klimant, 201174 | Retrospective | 426 patients undergoing surgery for breast cancer | After adjusting for age, disease stage and treatment, no significant differences were observed in 5-year OS and disease-free survival |
| Yu, 201275 | Retrospective | 468 patients with triple-negative breast cancer | Compared to women with blood type O, there was no significant difference in breast-cancer specific mortality for blood types A, B, or AB |
OS: overall survival; HR: hazard ratio; CI: confidence interval.